Richard Gaynor, M.D., joined our Board in 2021 and serves as Chair of the Research and Development Committee, and as a member of the Compensation Committee.
Dr. Gaynor is an experienced oncologist who brings to our Board deep expertise in research and development and significant experience as a senior business executive in the biopharmaceutical industry.
Dr. Gaynor is the President and Chief of Research and Development at BioNTech US (formerly Neon Therapeutics, Inc.), after serving in this role at Neon Therapeutics beginning in 2016. Previously, Dr. Gaynor spent 15 years in various senior clinical development and medical affairs roles at Eli Lilly and Company from 2002 to 2016, including as Senior Vice President of Clinical Development and Medical Affairs. Previously, he served as a Professor at the UCLA School of Medicine for nine years and on the faculty at the University of Texas Southwestern Medical School for eleven years, including as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center.
In addition to serving on our Board, he has also served on other public company boards, including Alkermes plc (Nasdaq) since 2019.
Dr. Gaynor is the author of nearly 150 publications and participates on numerous advisory boards and committees, including currently serving as a Director for the Damon Runyon Cancer Research Foundation and on committees for the American Association of Cancer Research and other cancer organizations.
Dr. Gaynor received an M.D. from the University of Texas Southwestern Medical School, where he served a residency in internal medicine. He completed fellowship training in hematology-oncology at the UCLA School of Medicine.
What is Richard Gaynor's net worth?
The estimated net worth of Richard Gaynor is at least $1.02 million as of March 17th, 2026. Dr. Gaynor owns 56,630 shares of Zai Lab stock worth more than $1,024,437 as of March 23rd. This net worth approximation does not reflect any other investments that Dr. Gaynor may own. Learn More about Richard Gaynor's net worth.
How do I contact Richard Gaynor?
Has Richard Gaynor been buying or selling shares of Zai Lab?
Over the course of the past ninety days, Richard Gaynor has bought $32,733.21 in shares of Zai Lab stock. Most recently, on Tuesday, March 17th, Richard Gaynor bought 1,731 shares of Zai Lab stock. The stock was acquired at an average cost of $18.91 per share, with a total value of $32,733.21. Following the completion of the transaction, the director now directly owns 56,630 shares of the company's stock, valued at $1,070,873.30. Learn More on Richard Gaynor's trading history.
Who are Zai Lab's active insiders?
Zai Lab's insider roster includes Rafael Amado (President, Head of Global Research and Development), Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), Richard Gaynor (Director), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?
During the last twelve months, Zai Lab insiders bought shares 2 times. They purchased a total of 11,731 shares worth more than $321,833.21. During the last twelve months, insiders at the sold shares 26 times. They sold a total of 360,570 shares worth more than $11,672,592.13. The most recent insider tranaction occured on March, 17th when Director Richard Gaynor bought 1,731 shares worth more than $32,733.21. Insiders at Zai Lab own 5.0% of the company.
Learn More about insider trades at Zai Lab. Information on this page was last updated on 3/17/2026.
